Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome.
Thurman AJ, Potter LA, Kim K, Tassone F, Banasik A, Potter SN, Bullard L, Nguyen V, McDuffie A, Hagerman R, Abbeduto L. Thurman AJ, et al. Among authors: potter la, potter sn. J Neurodev Disord. 2020 Apr 22;12(1):12. doi: 10.1186/s11689-020-09315-4. J Neurodev Disord. 2020. PMID: 32316911 Free PMC article. Clinical Trial.
New Targeted Treatments for Fragile X Syndrome.
Protic D, Salcedo-Arellano MJ, Dy JB, Potter LA, Hagerman RJ. Protic D, et al. Among authors: potter la. Curr Pediatr Rev. 2019;15(4):251-258. doi: 10.2174/1573396315666190625110748. Curr Pediatr Rev. 2019. PMID: 31241016 Free PMC article. Review.
Metformin treatment in young children with fragile X syndrome.
Biag HMB, Potter LA, Wilkins V, Afzal S, Rosvall A, Salcedo-Arellano MJ, Rajaratnam A, Manzano-Nunez R, Schneider A, Tassone F, Rivera SM, Hagerman RJ. Biag HMB, et al. Among authors: potter la. Mol Genet Genomic Med. 2019 Nov;7(11):e956. doi: 10.1002/mgg3.956. Epub 2019 Sep 14. Mol Genet Genomic Med. 2019. PMID: 31520524 Free PMC article.
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
Othman T, Moskoff BN, Ho G, Tenold ME, Azenkot T, Krackeler ML, Fisch SC, Potter LA, Kaesberg PR, Welborn JL, Wun T, Esteghamat NS, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. Othman T, et al. Among authors: potter la. Leuk Res. 2022 Aug;119:106885. doi: 10.1016/j.leukres.2022.106885. Epub 2022 Jun 8. Leuk Res. 2022. PMID: 35738024 Free article.
Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001.
McCoach CE, Rolfo C, Drilon A, Lacouture M, Besse B, Goto K, Zhu VW, Tan DSW, Farajian S, Potter LA, Kherani JF, Soldatenkova V, Olek EA, Muehlenbein CE, Park K. McCoach CE, et al. Among authors: potter la. J Thorac Oncol. 2022 Jun;17(6):768-778. doi: 10.1016/j.jtho.2022.02.004. Epub 2022 Feb 17. J Thorac Oncol. 2022. PMID: 35183775 Free PMC article.
29 results